Molecular Diagnosis: PCR, Hybridisation Probes and ELISA

Why detecting a small molecular signal matters

In an early stage of infection, the concentration of a pathogen or a measurable protein may be low, and clinical symptoms may not yet be obvious. Molecular diagnostic methods use biological specificity to detect a selected molecule rather than wait for an advanced disease state. Some methods identify nucleic-acid sequences of pathogens or human genes; others use the binding of a particular antigen to a matching antibody. Early detection can help when the correct molecular target is present and the assay is validated. It is not guaranteed for every infection, since collection technique, timing and test performance remain important.

PCR uses controlled cycles of DNA copying

Polymerase chain reaction, or PCR, amplifies a selected DNA segment in a sample. A typical reaction contains template DNA, two primers that flank the target, a thermostable DNA polymerase, nucleotide triphosphates and a suitable reaction mixture. Repeated cycles create more copies of the chosen DNA region. During denaturation, the two template strands separate; during annealing, primers bind to complementary positions; during extension, polymerase adds nucleotides to the growing strand in the 5′ to 3′ direction. The first newly made products become templates in later cycles, allowing amplification.

The theoretical number of double-stranded target molecules can double after each ideal PCR cycle. If one molecule amplifies perfectly, there are two after the first cycle, four after the second, eight after the third and thirty-two after the fifth. For N₀ starting copies and n ideal cycles, the approximate relationship is N = N₀ × 2ⁿ. Real assays do not maintain perfect doubling indefinitely because enzymes, primers and other reagents become limiting, reaction products accumulate and non-specific amplification may occur. The theoretical formula illustrates sensitivity, not a promise of exact copy number in clinical samples.

PCR can detect specific pathogen sequences or human genetic variants when the relevant primers and assay design are appropriate. Because HIV has an RNA genome, direct detection of viral RNA requires a reverse-transcription step to form complementary DNA, followed by amplification; this is commonly referred to as reverse-transcription PCR in molecular testing. Standard DNA PCR cannot amplify RNA templates without such conversion. Likewise, a negative PCR result does not automatically exclude an infection if sampling occurs before the target becomes detectable or if the target sequence differs from the assay design.

Hybridisation probes recognise complementary nucleotide sequences

A nucleic-acid probe is a short, selected DNA or RNA sequence with a detectable label. When exposed to a sample under suitable conditions, the probe can bind complementary target nucleic acid through Watson–Crick base pairing. The label may be radioactive, fluorescent or another detectable chemical group. A historical method uses labelled probes followed by autoradiography to reveal sites where radioactive probe has remained bound. The scientific principle is sequence-specific hybridisation, and the signal indicates that binding conditions and target complementarity allowed detection.

The source describes a mutation that prevents the matching probe from being detected. This can occur when the probe is designed to discriminate a particular sequence and the mutation sufficiently weakens hybridisation. It is not true that every mismatch completely prevents probe binding under all circumstances. Probe length, temperature, sequence and wash conditions influence whether partially matched strands remain attached. Molecular testing therefore uses appropriate controls and verified thresholds to distinguish a truly negative sample from a weak or ambiguous signal.

ELISA uses highly specific antigen–antibody interactions

Enzyme-linked immunosorbent assay, or ELISA, is a family of detection formats based on antibodies binding their corresponding antigens. In one arrangement, an immobilised capture antibody binds a target antigen, and a detection antibody together with an enzyme-linked reporter produces a measurable signal. In another arrangement, a known antigen can capture antibodies made by the patient. The resulting colour or other signal depends on the detection chemistry. The essential distinction is what the test is designed to measure: pathogen-associated antigen or the host's antibody response.

A positive antibody test may indicate previous exposure, vaccination or an ongoing infection depending on the antigen and antibody class being measured. Early in a new infection, antibodies may not yet be detectable, while a direct antigen or nucleic-acid test may detect infection earlier in selected circumstances. Conversely, a detectable nucleic acid does not always establish that the organism is still viable or clinically responsible for a person's symptoms. Interpretation must integrate assay performance, specimen, timing and the actual clinical question.

Comparing direct and indirect molecular evidence

PCR and related nucleic-acid tests answer whether a specified sequence is present in the sample; they rely on nucleic-acid recognition and amplification. Hybridisation probes answer whether sequence matching is sufficient to form a detectable complex. ELISA or similar immunoassays can answer whether particular antigens or antibodies are present. No one method replaces all others. When a disease is suspected, clinicians choose a test based on likely agent, timing of exposure, accessible specimen and acceptable accuracy. This is why modern diagnostics are best described as complementary tools rather than a list of machines.

Quick Quiz